Claims for Patent: 6,576,418

Summary for Patent: 6,576,418

Title:	Method for determining the nucleotide sequence of the gene for the .alpha.5(IV) chain of human type IV collagen
Abstract:	The present invention relates to a method for isolating and identifying the nucleotide sequence of the human gene for the type IV collagen .alpha.5(IV) chain. The present invention is directed to the determination of the nucleotide sequence of the gene for the .alpha.5(IV) collagen chain in individuals by any method known to the art, e.g. cloning from genomic DNA libraries or amplifying gene regions with the polymerase chain reaction (PCR) and studying their physical properties or nucleotide sequences. In addition, the invention is directed to the use of the nucleotide sequences of the .alpha.5(IV) gene to amplify or identify the nucleotide sequences of the .alpha.5(IV) gene.
Inventor(s):	Tryggvason; Karl (Oulu, FI), Hostikka; Sirkka L. (Oulu, FI), Zhou; Jing (Oulu, FI)
Assignee:	BioStratum, Inc. (Durham, NC)
Application Number:	08/692,989
Patent Claims:	1. A process for isolating and identifying genomic DNA clones which code for a portion of the .alpha.5 (IV) gene of human type IV collagen, said portions comprising gene fragments as set forth in SEQ ID NOs: 1-19, wherein the process comprises the steps of: a) labeling a nucleic acid selected from the group consisting of SEQ ID NOS: 1-19 or cDNAs corresponding thereto with a detectable label; b) screening a genomic library with the labeled nucleic acids obtained in step a) in order to isolate those genomic clones containing coding regions of the human type IV collagen .alpha.5 (IV) chain comprising gene fragments as set forth in SEQ ID NOs: 1-19; c) isolating the genomic clones obtained in step b) that contain coding regions of the gene for the human type IV collagen .alpha.5 (IV) chain; d) cloning the isolated genomic clones of step c) into a vector and inserting the vector into a bacterial or other host; and, e) sequencing said genomic clones of steps d) thereby identifying the isolated genomic DNA clones comprising SEQ ID NOs: 1-19. 2. The process of claim 1, wherein the genomic library comprises a human lymphocyte genomic library. 3. An isolated gene fragment consisting of any one of the sequences set forth in SEQ ID NOs: 1-19. 4. A process for identifying differences in the nucleotide sequence of a portion of the gene coding for .alpha.5 (IV) polypeptide chain of human type IV collagen comprising the steps of: a) labeling a nucleic acid selected from the groups consisting of SEQ ID NOs: 1-19 or cDNAs corresponding thereto with a detectable label; b) screening a genomic library with the labeled nucleic acids obtained in step a) in order to isolate those genomic clones containing coding regions of the portion of the human type IV collagen .alpha.5 (IV) chain; c) isolating the genomic clones obtained in step b) that contain coding regions of the portion of the gene for the human type IV collagen .alpha.5 (IV) chain; d) cloning the isolated genomic clones of step c) into a vector and inserting the vector into a bacterial or other host; e) sequencing said genomic clones of step d); f) identifying coding (EXON), intervening (intron) and flanking sequences of the portion of the gene for the human .alpha.5 (IV) type IV collagen chain; and, g) identifying differences between the portions of the genes for the human .alpha.5 (IV) type IV collagen chain independently obtained by the process comprising steps a)-f) above by comparing said sequences. 5. A method for identifying the size of a restriction fragment of the portion of the human type IV collagen .alpha.5 chain (COL4A5) gene which comprises: a) contacting separated restriction fragments obtained from a restriction enzyme digest of DNA of an individual with one or more detectable probes consisting of SEQ ID NO: 1-19 or cDNAs corresponding thereto. b) comparing the restriction fragment pattern so produced with a restriction fragment pattern obtained from an identical restriction enzyme digest of DNA from another individual; c) identifying the variation in fragment sizes between individuals.

Details for Patent 6,576,418

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2009-07-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2009-07-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2009-07-07